Buckingham Research Upgrades Allergen (AGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Six dead in 'stampede-like' incident at India temple, ANI says
Analyst Comments on Allergen (AGN) as Investors Await Updated Valeant (VRX) Proposal
May 27, 2014 1:57 PM EDTWells Fargo maintained an Outperform rating on Allergen (NYSE: AGN). Analyst Larry Biegelsen expects Valeant Pharmaceuticals International (NYSE: VRX) to update its proposal tomorrow.
"VRX is expected to raise its bid for AGN tomorrow, perhaps including a higher cash component. We have to wait-n-see on the higher bid and AGN's ultimate response.... More
